Translational studies of syndecan-1 as angiogenesis inhibitor : from basic research to clinical applications by Javadi, Joman
From Department of Laboratory Medicine 
Karolinska Institutet, Stockholm, Sweden 
TRANSLATIONAL STUDIES OF SYNDECAN-1 AS 
ANGIOGENESIS INHIBITOR - FROM BASIC RESEARCH 






All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB, 2021  
© Joman Javadi, 2021 
ISBN 978-91-8016-214-2 
Cover illustration: Front cover is design by Iman Shahbandeh and illustrates the main concept 
of the thesis combined with a poem by Hussein Panahi that says: 
Behind this window, science is talking about sun while holding an umbrella of doubt. 
   
 
 
TRANSLATIONAL STUDIES OF SYNDECAN-1 AS 
ANGIOGENESIS INHIBITOR – FROM BASIC 
RESEARCH TO CLINICAL APPLICATIONS 
THESIS FOR DOCTORAL DEGREE (Ph.D.)  
By 
Joman Javadi  
The thesis will be defended in public at 4X, Entreplan, Alfred Nobels Alle 8, Huddinge, 
2021/05/21 at 10:00 am 
Principal Supervisor: 
Professor Katalin Dobra 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Pathology  
 
Co-supervisor(s): 
Professor Emeritus Anders Hjerpe  
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Pathology 
 
Ph.D. Daniel Hagey 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of BCM 
Opponent: 
Professor Jeremy Turnbull 
Liverpool University 




Professor Lena Kjellén 
Uppsala University 




Professor Birgitta Sander 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Pathology 
 
Professor Staffan Strömblad 
Karolinska Institutet 






                                                                                                  
 
                                                                                  To my beloved Sam 























                                                                                 Do not go with the flow. Be the flow.   
                                                                                                                           Elif Shafak                                     
 
 
POPULAR SCIENCE SUMMARY OF THE THESIS 
Asbestos is a group of minerals that are found in soil and rocks in many parts of the world. 
Asbestos fibers are strong, resistant to heat and do not conduct electricity. Because of these 
characteristics, they are useful in the industry. Asbestos fibers are in the air and when they are 
inhaled, they stick to mucus in the throat and end up in the lungs and the mesothelial surface. 
These fibers injure the mesothelial cells and cause chronic inflammation, DNA damage and 
finally malignant mesothelioma.  
Malignant Mesothelioma (MM) is an aggressive and uncurable type of cancer that is up to 
80% caused by asbestos. People who worked with asbestos or have been exposed to it (male 
are involved more than female) have the highest risk of getting mesothelioma cancer.  
It usually takes 20-50 years after asbestos exposure for the tumor to appear, and once 
diagnosed most patients has a short survival time (in the order of one year or less). There are 
four different locations of MM within the body, the most common involves the pleural. 
Shortness of breath, chest pain, loss of weight, vomiting, coughing blood and increasing of 
the pleural fluid are first symptoms for pleural malignant mesothelioma.  
Attempts to treat the tumor can involve surgery, radiation, or chemotherapy. Surgery can in 
some countries be an option during early stages of the disease, although the benefits of this 
option are still questioned. During more advanced stages treatment is confined to 
chemotherapy, sometimes supported by radiotherapy. Although today’s therapeutic options 
will not cure the patient, therapy of mesotheliomas will have better effects n early stages and 
when initiated soon after diagnosis. It is therefore urgent to learn more about the progression 
of mesothelioma progression, in order to detect the tumor earlier and, if possible, tailor 
treatment options for this particular kind of tumor. 
The aim of this thesis was to study the role of Syndecan-1 (a cell membrane protein) in 
malignant mesothelioma angiogenesis, the ability of the tumor to disseminate, the survival of 
patients, and to find useful biomarkers to be analyzed in parallel. For this purpose, in paper I 
we identified angiogenesis-related genes which were affected by Syndecan-1. Moreover, we 
showed that higher level of syndecan-1 inhibits proliferation, tube formation and wound 
closure in endothelial cells. In paper II we studied the effect of Syndecan-1 on epithelial-
mesenchymal transition of lung cancer (A549) and fibrosarcoma (B6FS) cell lines. We 
showed that syndecan-1 overexpression associated with less invasive fibrosarcoma cells.  
In addition to this, in paper III we focused on finding novel biomarkers for earlier diagnosis 
of the disease. We found nine diagnostic biomarkers for malignant mesothelioma. 
Additionally, we showed that four out of nine of these biomarkers can be used for 
distinguishing malignant mesothelioma from lung carcinoma. In paper IV, we characterized 
extracellular vesicles, isolated from pleural fluid. We showed that these small vesicles carry 
biological molecules which can affect other tumor and non-tumor cells behavior in the 
extracellular environment.  
More studies to better understand the mechanisms involved in malignant mesothelioma 
progression are required. Additionally, combining several biomarkers can help us promote 









Malignant mesothelioma (MM) is a highly aggressive primary tumor of the pleura, associated 
with poor prognosis. MM is mainly related to exposure to mineral fibers such as asbestos. 
The diagnosis of MM, despite multiple diagnostic tools, is challenging and treatment options 
are limited. Previous studies have shown that angiogenesis plays an important role in MM 
progression thus, anti-angiogenic agents show promising use in MM therapy. In addition to 
that, detection of new soluble diagnostic or prognostic biomarkers may improve patients’ 
outcomes and therapeutic options. 
Syndecan-1 (SDC-1) is a membrane proteoglycan which regulates various biological 
processes in tumor cells by acting as a co-receptor for growth factors. SDC-1 is also a 
significant mediator of cell-cell and cell-matrix interactions. Cell membrane SDC-1 can be 
shed by sheddases and its Heparan Sulfate (HS) degraded by heparanase-1 (HPA-1). 
Additionally, syndecan-1 can translocated to the nucleus through a tubulin-dependent 
mechanism. Loss of cell membrane SDC-1 is associated with epithelial-mesenchymal 
transition (EMT) and worse prognosis, while nuclear translocation of SDC-1 seems to have 
the opposite effect. 
The purpose of this thesis work was to investigate the role and potential value of syndecan-1 
as an angiogenic factor and as a diagnostic biomarker for MM.   
We showed the inhibitory effect of SDC-1 overexpressing mesothelioma cells on migration, 
proliferation, and tube formation capacity in endothelial cells. We also found that silencing of 
SDC-1in MM cells promoted experimental wound closure but had no effect on tube 
formation in endothelial cells (paper I). These effects were mediated by angiogenic factors 
comprising Angiopoietin-1, FGF-4, HGF, TGF-β1, TIMP-1, TSP-1, and TRG1-β1 which 
were significantly up- or down regulated by SDC-1 overexpression, as well as IL8 which was 
significantly up-regulated by SDC-1 silencing. In the same study, we evaluated the 
expression level of SDC-1 and VEGF in pleural effusion and showed the prognostic value of 
VEGF in malignant mesothelioma patients.  
We furthermore studied the potential value of Angiopoietin-1, HGF, and TIMP-1 among 
other angiogenic-related proteins as diagnostic and prognostic biomarkers in patient material. 
We found that Galectin-1, Mesothelin, Osteopontin, VEGF, HGF, shed SDC-1, MMP-7, 
NRG1-β1, and TIMP-1 were significantly higher in malignant pleural mesothelioma patients. 
Additionally, we showed that shed SDC-1, MMP-7, Mesothelin, and Galectin-1 significantly 
discriminated MM from metastatic adenocarcinoma patients (paper III). We further verified 
our result in paper I and showed that shed SDC-1 and VEGF were prognostic in MM 
patients. 
The role of nuclear SDC-1 on epithelial-mesenchymal plasticity of tumor cells – a key event 
in tumor spread and metastasis – was studied in paper II. Using tumor cell lines, we found 
that loss of nuclear SDC-1 was associated with cellular elongation and induced EMT in 
human lung adenocarcinoma cells. Further investigation revealed that nuclear SDC-1 reduce 
mesenchymal properties and invasiveness of fibrosarcoma cells. 
Extracellular vesicles have recently gained much interest for their ability to mediate cell-to-
cell communication. In paper IV we characterized extracellular vesicles including, apoptotic 
bodies, microvesicles, and exosomes, derived from pleural effusion from malignant pleural 
mesothelioma, metastatic lung adenocarcinoma, and benign patients. We found that the size 
of exosomes was in accordance with previous studies, but their concentration varied between 
individuals in the same patients group. Additional characterization showed that the presence 
of CD2, CD8, CD9, CD81, CD24, CD44, CD105, CD146, CD133, MCSP, and ROR1 were 
higher in the exosome fraction compared with microvesicles and apoptotic bodies whereas, 
CD40 and CD45 were lower. Furthermore, we demonstrated the presence of the angiogenesis 
-related proteins which we studied in paper III in extracellular vesicles.     
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The key to growth is the introduction of higher dimensions of consciousness into our 
awareness. 
                                                                                                                        Lao Tzu 
 
1.1 PLEURAL EFFUSION  
1.1.1 Structure of the normal pleura 
The lungs are enclosed by the pleura, which consists of mesothelial cells. The flat superficial 
mesothelial cells rest on a basement membrane under which fibroblast-like mesothelial cells 
are found. The pleura also covers the thoracic wall, thus the inner visceral layer and the outer 
parietal layer form together the pleural cavity. This cavity is one out of four serous cavities in 
the body (the others are pericardium, peritoneum, and tunica vaginalis testis in male). In 
adults, the pleural cavity contains physiologically a tiny amount (0.1 – 0.3 ml/kg) of pleural 
fluid which is secreted from the vasculature of parietal and absorbed into the lymphatic 
circulation. Under normal conditions the pleural fluid has mainly two functions which are, 
lubricating the pleural surface to allow frictionless movements during breathing, and 
generating surface tension between inner and outer layer of the pleura. The second function 
allows the thoracic cavity to expand during inhalation [1-3]. 
1.1.2 Etiology and pathogenesis  
Oncotic and hydrostatic pressure gradient between parietal and visceral blood capillaries 
regulate secretion, volume, and movement of pleural fluid. Lymphatic vessels in the parietal 
pleura drains pleural fluid into lymphatic capillaries. In normal conditions, there is a balance 
between production and resorption of the fluid [4]. Accumulation of pleural fluid is due to a 
wide variety of pathologic conditions and diseases such as heart failure, pleural infections, 
and malignancies, either because of excessive production or decreased resorption of the fluid 
or both [5, 6]. Pleural fluids caused by altered hydrostatic and/or oncotic pressure are 
classified as transudate. Exudates, on the other hand, is caused by increased vessel 
permeability, this fluid showing higher concentration of proteins. Heart failure, liver 
cirrhosis, nephrotic syndrome and other causes of hypoalbuminemia are common causes of 
transudate whereas, exudates are seen in inflammatory processes and in malignancies [6, 7]. 
1.1.3 Management and treatment   
 Congestive heart failure, pleuro-pneumonia, and cancer are the most common causes of 
pleural effusions (PE). If a pleural effusion is suspected, physical examinations, chest x-ray, 
computerized tomography (CT) scan, chest ultrasound, and patient’s clinical history are 
required to reveal the etiological causes of effusion. From clinical point of view, chest 
imaging and measuring PE/serum ratio of total protein and LDH, and PH are useful to 
diagnose and distinguishing transudate from exudate [7-9]. Patients with PE might present 
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symptoms such as dyspnea, pleuritic chest pain, and dry cough or be asymptomatic 
depending on the volume of pleural fluid. Thoracentesis and thoracoscopy are therapeutic 
options for treatment and relief of dyspnea and chest pain of the patients [10].   
 
1.2 MALIGNANT MESOTHELIOMA 
1.2.1 Etiology and pathogenesis   
Malignant mesothelioma (MM) is a highly aggressive, and so far, incurable primary tumor of 
mesothelial cells. MM is mainly caused by exposure to mineral fibers such as asbestos [11, 
12]. Asbestos consists of crystalline silicates fibers that cause oxidative stress and chronic 
inflammation. These processes lead to alteration of gene expression and intracellular 
signaling pathways through generation of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). Up-regulation of nitric oxide radical and peroxynitrite ion by 
asbestos lead to DNA damage and modification of DNA bases from G to T. Previous studies 
showed that phosphorylation of epidermal growth factor receptor (EGFR) by reactive oxygen 
species in rat mesothelial cells, leads to activation of extracellular-regulated kinases (ERKs). 
Activation of ERKs is linked to cellular processes such as cell proliferation, differentiation, 
and apoptosis. The duration of exposure and type of asbestos correlate with the risk of 
developing malignant mesothelioma [13-16]. Erionite, radiation, simian virus 40 (SV-40) and 
genetic predispositions such as BRCA1-associated protein 1 (BAP1) gene are less common 
risk factors for MM. Malignant mesothelioma has a high mortality rate and occurs after a 
long (20 to 50 years) latency period between commencement of asbestos exposure and 
diagnosis. The survival time after diagnosis is less than one year [17, 18]. 
1.2.2 Localization of malignant mesothelioma 
Malignant pleural mesothelioma (MPM) is the most common (70%), arising of mesothelial 
cells of the pleura. Most cases of malignant pleural mesothelioma start by inhalation of 
asbestos fibers that later are captured in lungs and mesothelial cells. MPM has a poor 
prognosis, short survival time and no effective treatment options [19, 20]. Dyspnea and 
pleural effusion are common first symptoms of MPM [21]. 
Less than 30% of malignant mesothelioma cases originate from peritoneum. Compared to 
MPM, it seems to be less associated to asbestos exposure and more often develops in younger 
individuals and in women. Median survival time is less than eight months, but cytoreductive 
surgery (CRS) in early-diagnosed patients may increase this time to 30-90 months [22, 23]. 
Pericardial mesothelioma is rare (< 1%) and aggressive with a shorter survival time of 5-7 
months compering with pleural and peritoneum mesothelioma. Chest pain, shortness of 
breath, cardiac tamponade, heart failure, constrictive pericarditis and pericardial effusion are 
pericardial mesothelioma’s symptoms [24]. 
Malignant pleural mesothelioma is the subject of this thesis and from now on I will focus on 
this type of malignant mesothelioma. 
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1.3 MALIGNANT PLEURAL MESOTHELIOMA 
1.3.1 Epidemiology of malignant pleural mesothelioma 
Asbestos exposure is the main risk factor in 90% of the cases. Although asbestos is banned in 
most developed countries, in Russia, India, Brazil, and China it is still in use. Consequently, 
the incidence of MPM will increase in the next few decades due to earlier asbestos exposure 
and a long latency period until the disease develops [25, 26]. Hence, more diagnostic 
biomarkers for earlier detection of MPM will be needed.    
1.3.2 Diagnosis of malignant pleural mesothelioma 
The diagnosis of MPM can be obtained in different ways. It can be based on histological 
biopsy material or the cytological evaluation of cells in an effusion. Although not considered 
sufficient for a definitive diagnosis, the analysis of soluble biomarkers in the pleural effusion 
may offer strong support to effusion cytology.  
Malignant pleural mesothelioma is often diagnosed at a late stage when the tumor cells are 
less responsive to current therapies. The survival time of the patients are only in the order of 
one year. Over the past decade, improving diagnostic and prognostic tools has been subject of 
considerable interest. 
1.3.2.1  Histological and cytological diagnosis 
Histological diagnosis is based on both morphology and positive immunohistochemical 
markers for mesothelial cells such as calretinin and Wilms tumor 1 (WT-1) and excluding 
markers such as BerEp4 and CEA. 
Histologically, malignant pleural mesothelioma is classified into three subtypes: epithelioid 
(60-80%), sarcomatoid (<10%) and biphasic (10-15%) [27]. These features can be identified 
by routinely stained tissue. The epithelioid subtype contains polygonal, oval, or cuboidal cells 
is less aggressive with longer survival time, comparing with the sarcomatoid subtype which 
contains spindle cells. The biphasic subtype of MPM contains both epithelioid and 
sarcomatoid cells in the same tumor [17, 27, 28] and the proportion of epithelioid or 
sarcomatoid component determines the survival time. 
Pleural effusion is a common symptom of MPM and often the first available material for 
cytological diagnosis. Sensitivity of the cytological diagnosis varies in different laboratories 
between 30%-75%. The difficulty of the diagnosis lies in overlapping of the atypical features 
and immunoreactivity among benign and malignant cells [28]. Cytological examination of an 
effusion often reveals abundant mesothelial cells with various degree of atypia arranged 
frequently in 3D papillary structures. Some MPM effusions are, however, devoid of such 
typical cytomorphology, and the cytological diagnosis must always be based on typical 
immunocytochemical reactivities. When the cytomorphological diagnosis obtained, 
combining morphology with immunocytochemistry, and also supported by ploidy analyses, 
using fluorescence in-situ hybridization (FISH); a definitive diagnosis of MPM can be 
obtained up to 73% of all cases. Like in histopathology these adjuvant methods are 
compulsory for a reliable diagnosis [27, 29]. 
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1.3.2.2 FISH and IHC/ICC diagnostic markers 
The pathological diagnosis and distinguishing benign from malignant conditions are 
challenging. Hence, additional methods are used to further support diagnosis and differentiate 
MPM from benign and other types of cancer. A variety of IHC markers such as the BRCA1 
associated protein 1 (BAP1), HEG homolog 1 (HEG-1), methyladenosine phosphorylase 
(MTAP), glucose transporter 1 (GLUT-1), epithelial membrane antigen (EMA), desmin, 
CD44 molecule (CD44), and FISH analysis of cyclin dependent kinase inhibitor 2A 
(CDKN2A) gene, better known as p16, are useful for diagnosis of MM. Among these 
markers, evaluation of BAP1 by immunohistochemistry and homozygous deletion of p16 by 
FISH are considered specific for defining a malignant condition, i.e., distinguishing MM 
from reactive mesothelial proliferations [30, 31]. 
BRCA1-associated protein1 (BAP1) is a tumor suppressor which regulates cell cycle, cell 
proliferation and cell death. Mesothelioma cells often show somatic mutation of BAP1 gene 
which correlates with loss of nuclear immunohistochemical staining while benign and 
inflammatory cells retain the IHC staining even with one wild-type copy of BAP1. Desmin is 
a muscle marker which in a similar way is not expressed in malignant mesothelial cells. 
BAP1 and desmin are markers commonly used to distinguish benign and malignant 
mesothelial populations by immunocytochemistry [30, 32]. 
A common genetic alteration in MM is the homozygous deletion of cyclin-dependent kinase 
inhibitor 2A (CDKN2A), also known as p16. Loss of p16 gene in tissue sections or pleural 
effusion cytology specimens can be detected by fluorescence in situ hybridization (FISH). 
The two major benefits of p16 FISH analysis are that no benign samples show homozygous 
loss of p16 and it give prognostic information. Deletion of p16 gene correlates with more 
aggressive tumor [30, 33]. 
1.3.2.3 Soluble biomarkers 
Earlier diagnosis may provide better chances for successful chemotherapy. Generally, a 
biomarker is a measurable distinctive indicator of a certain biological process that can help 
with the diagnosis, hopefully leading to better patient prognosis. So far, several diagnostic 
and prognostic biomarkers have been investigated for MM including mesothelin, hyaluronan, 
osteopontin, and miRNAs [34, 35]. 
Mesothelin  
Mesothelin is a 71-KDa blood-based precursor protein which expressed at low level in 
normal mesothelial cells of pleura, peritoneum and pericardium [36]. Mesothelin can be 
cleaved by endoprotease furin into two proteins: a shed form (N-terminal megakaryocyte-
potentiating factor (MPF)), which is secreted into the blood, and a membrane- bound 
mesothelin (C-terminal glycosylated phosphatidylinositol-linked glycoprotein) [17, 37]. 
Soluble mesothelin can be released from the cell to the blood and pleural effusion. Several 
studies have shown that, this shed form of mesothelin is elevated in many cancers including 
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MPM, ovarian cancer and pancreatic cancer. There is a correlation between expression level 
of soluble mesothelin and tumor size and survival time. Therefore, mesothelin can be used as 
diagnostic and prognostic marker for MPM [38-40]. 
Hyaluronan 
Hyaluronan (Hyaluronic acid/HA), a member of glycosaminoglycan family, is a negatively 
charged high-molecular-weight (HMW) polysaccharide (4–800 KDa) which consists of the 
repeating disaccharide (glucuronic acid and N-acetylglucosamine). HA is a widely distributed 
component of ECM in normal connective tissues. Different cellular processes including cell 
migration, differentiation, cell growth and adhesion are influenced by this 
glycosaminoglycan. Hyaluronic acid is often highly expressed in pleural effusion and serves 
as a diagnostic biomarker for MPM [41-44]. 
Osteopontin 
Osteopontin (OPN) is a calcium-binding glycol-phosphoprotein which is secreted by 
osteoclasts, cardiac fibroblasts, macrophages and activated T cells. Binding of osteopontin to 
its receptors (αvβ1, αvβ3, αvβ5 and CD44) play roles in tumor development, cell migration 
and cell matrix interaction. Higher levels of osteopontin in serum, plasma and pleural 
effusion have been found in MPM patients compared with benign subjects. Hence, 
osteopontin can be used as another diagnostic marker for MPM [45-47]. 
Micro-RNAs 
Micro-RNAs (miRNAs) are short (~22 nucleotides) single strand non-coding RNAs that are 
involved in differentiation, proliferation, and apoptosis by regulating the gene expression at 
the post-transcriptional levels. It is important to note that alterations in the expression pattern 
and level of miRNAs associates to carcinogenesis. The expression of several miRNAs is 
altered in MPM (miR-30b*, miR-195*, miR-32*, miR-584, miR-483-3p, miR-9, miR-7-1* 
etc.). In addition, miR-143, miR-210 and miR-200c distinguishing MPM from primary and 
metastatic lung adenocarcinoma and benign diseases. Data suggest that miRNAs can be used 
as diagnostic biomarkers for MPM [48-50]. 
Exosomes 
Exosomes are small membrane nanovesicles (30-150 nm) of endosomal origin that are 
secreted by different cell types including epithelial and tumor cells. Exosomes contain nucleic 
acids (including DNA, mRNA, noncoding RNA, and microRNA), and signaling proteins 
(transmembrane and cytoskeletal proteins) which are involved in various functionalities of 
the tumor cells including, the establishment of tumor environment, tumor growth and 
progression. Exosomes are released in abundance from tumor cells into different body fluids 
and can be used as biomarkers and cell-cell or cell-matrix interactions mediators [51-55].  
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1.3.3 Molecular processes in malignant pleural mesothelioma 
Alterations in gene expression and loos of protein function are frequent in MPM. Loss of 
heterozygosity (LOH) leads to alteration of some tumor suppressor genes (TSGs) such as 
p14, p15, p16 at 9p21, NF2 at 22q12, and BAP-1 at 3p21 in MPM [56, 57]. Homozygous 
deletion of 9p21 (CDKN2A gene), results in loss of p16INK4a and p14ARF, which are cell 
cycle regulators. p53 and pRb are indirectly inactivated in MPM. p14ARF stabilizes p53 
through inactivation of MDM2 and p16INK4a stabilizes pRb by inhibiting CDK4/6 [58]. 
In addition to inactivation of tumor suppressor genes, activation of transcription factors such 
as activator protein-1 (AP-1) and β-catenin also regulate a variety of cellular processes 
including proliferation and apoptosis [59]. Moreover, many growth factors such as vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic fibroblast growth 
factor (bFGF), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF) A 
and B, and endothelial growth factor (EGF) are involved in the tumor development and 
pathogenesis of MPM (Figure 1) [60-65]. VEGF plays an important role in regulating 
angiogenesis of mesothelioma cells which has a prognostic value in MPM.  
 
 
              
Figure 1. A schematic diagram of the main players in pathogenesis of malignant mesothelioma. 
Several receptors and growth factors are activated by asbestos which leads to phosphorylation of RTKs and other 
transcription factors which promote cell proliferation, and inflammation. Genetic changes including mutations 








1.3.4  Epithelial to mesenchymal transition in malignant pleural 
mesothelioma 
Epithelial-to-mesenchymal transition (EMT) is a physiological and pathological process that 
occurs during cancer progression. It confers motility to the cancer cells necessary for 
invasiveness and subsequent metastasis. During EMT cells lose their cell-cell contacts 
(through disassembly of adherens-, tight-, and gap- junctions) and apical-basal polarity 
(through disruption of polarity complexes such as scribble (SCRIB) and partitioning 
defective (PAR)) [66, 67]. Additionally, cells change their transcriptional programs which 
leads to down-regulation of epithelial markers (E-cadherin, zonula occludens (ZO-1) and β-
catenin) and up-regulation of mesenchymal markers (vimentin, fibronectin, and smooth 
muscle actin (α-SMA). EMT is regulated by a variety of transcription factors including ZEB-
1, Snail, Twist (Figure 2) which down-regulate E-cadherin gene [68-70].  
The differentiation of MPM has a major impact on patient survival. The epithelioid subtype 
of MPM has a better prognosis compared to the sarcomatoid and biphasic subtypes, hence 
suggesting a role of EMT in malignant pleural mesothelioma [71, 72]. The EMT master 
regulator master genes, ZEB-1, Snail, and Twist are up-regulated in MPM. Among other 
growth factors including, HGF, TNF-α, FGF-2, and EGF induce EMT in MPM. TGF-β on 




Figure 2. The basic of epithelial-mesenchymal transition. Epithelial cells lose their polarity and cell-
cell contact and become mobile mesenchymal cells. Epithelial and mesenchymal markers are listed. MPM has an 
intermediate phenotype, co-expressing both epithelial and mesenchymal markers, but retained ability to shift 





1.3.5 Angiogenesis in malignant pleural mesothelioma 
Forming of new blood vessels or angiogenesis is a general prerequisite required for tumor 
growth and metastasis. Angiogenesis has an important role in the progression and 
invasiveness of cancer and its inhibition has become the target for intense development of 
malignant diseases treatment [74].  
Pro-angiogenic factors, secreted from tumor cells, are stimulating angiogenesis in solid 
tumors. Secretion of pro-angiogenic factors from tumor cells leads to creation of immature, 
and permeable blood vessels. There are several growth factors, including Vascular 
endothelial growth factor (VEGF), Transforming growth factors (TGF-β) families, and 
platelet-derived growth factor (PDGF), involved in the formation of defective new blood 
vessels. Additionally, a tumor angiogenetic phenotype is depending on the balance between 
pro-angiogenic and anti-angiogenic factors activity [75-78].  
In MPM, VEGF, matrix metalloproteinases (MMPs), hepatocyte growth factor (HGF), 
fibroblast growth factor-2 (FGF-2), PDGF, and interleukin-8 (IL-8) are positive regulators of 
angiogenesis. Among these angiogenic factors, VEGF is the most potent factor which 
significantly increases vascular permeability and tumor aggressiveness [79, 80]. VEGFs act 
via their receptors and this interaction leads to receptor dimerization and phosphorylation 
which furthermore leads to activation of signaling pathways. Bevacizumab (anti-VEGF 
antibody), Vendetanib (triple tyrosine kinase inhibitor) and E7080 (multi-tyrosine kinase 
inhibitor) are antibodies which neutralize VEGF activities. VEGF inhibitors in combination 
with chemotherapeutic agents such as pemetrexed will inhibit hyper-permeability and 
angiogenesis of endothelial cells which can be used as a therapeutic strategy against MPM 
[79]. In addition, Nintedanib, another receptor tyrosine kinase inhibitor (RTKI) that inhibits 
VEGF/FGF receptors 1-3, PDGF receptors α/β, and Src family [81, 82] has been proved to be 
effective in MPM. 
1.3.6 Treatment of malignant pleural mesothelioma    
Despite greater understanding of MPM tumorigenesis and advanced technologies, malignant 
pleural mesothelioma is still an often treatment resistant malignancy and its treatment 
remains a challenge. Depending on the tumor subtype, epithelioid, sarcomatoid and biphasic, 
median overall survival is 12-27, 7-18 and 8-12 months respectively [83, 84]. The main 
therapeutic strategies for MPM are, chemotherapy and surgery in combination with 
chemotherapy or radiotherapy (RT) or both, although an optimal treatment has not been 
established. Multimodality therapy of MPM including surgery followed by chemotherapy and 
radiotherapy may prolongs patient’s survival time [85, 86].  
Cancer immunotherapy is a new promising treatment option for MPM patients. The 
expression of immune-checkpoint proteins such as PD-L1 is altered in tumor cells. It has 
been shown that PD-L1 is overexpressed in sarcomatoid subtype of MPM. PD-L1/PD-1 is a 
negative regulator of active T-cells proliferation. Immune-check point inhibitors such as 
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pembrolizumab and nivolumab have shown promising development in many tumors 
including MM [87, 88]. 
1.4 SYNDECANS 
1.4.1 General features  
Proteoglycans (PGs) are biologically active macro-molecules, produced by most eukaryotic 
cells. PGs consist of a core protein with covalently attached glycosaminoglycan (GAG) 
chain. Proteoglycans, based on their protein core, composition of their GAG chain, 
localization, and size, are classified into three groups. Syndecans and glypicans are cell 
membrane proteoglycans [89, 90].  
The syndecan (SDC) family in vertebrates consists of four members (SDC-1, SDC-2, SDC-3, 
and SDC-4) and belongs to the type I transmembrane heparin sulfate proteoglycans family 
[91, 92]. In adult tissues, syndecan-1, which is the focus of this thesis, expressed mostly in 
the epithelial cells, syndecan-2 in connective tissues, syndecan-3 in neural tissues and 
cartilage while syndecan-4 is ubiquitously expressed [93]. The synthesis of the syndecan core 
proteins occurs in ribosomes whereas subsequent modification and binding of 
glycosaminoglycans occurs in Golgi. Later, Syndecans translocate to the cell membrane by 
exocytosis [94]. 
1.4.2 Syndecans structure 
 Syndecan core proteins have a similar structure, consisting of an extracellular domain, a 
highly conserved transmembrane domain, an intracellular domain of about 30 amino acid 
length [95, 96]. 
The extracellular domain (ED) of Syndecans carries covalently attached GAG chains that are 
regulating many of syndecans’s cellular functions [97]. The biosynthesis of the GAG side 
chains is performed by enzymes, such as exostosin glycosyl-transferases (Exts) and 
deacetylase-N-sulfotransferases (Ndsts), activity. Exts enzymes are required for HS chain 
elongation, by adding repeating disaccharide units, while Ndsts are required for HS chain 
modification, by N-deacetylation of N-acetylglucosamine residues and N-sulfation of same 
amino group [98-100].  
The transmembrane domain (TMD) of Syndecans plays role in dimerization and interaction 
of these proteoglycans with other receptors and proteins respectively [101-103]. This domain 
is highly homologous and contains GXXXG motif which modifies homo- and hetero-
dimerization of Syndecans. Additionally, the TMD transmits signals to the cytoplasmic 
domain which regulates cell signaling [104]. 
The cytoplasmic domain (CD) of Syndecans consists of two highly conserved regions (C1 
and C2) which flank a variable region (V1) [105, 106]. This domain of Syndecans mediates 
interaction of Syndecans with other cytoplasmic proteins. For example, binding of C1 region 
of syndecan-2 to ezrin/radixin/moesin (ERM) proteins links syndecan-2 to actin cytoskeleton. 
 
10 
Moreover, C region of syndecan-1 contains MKKK motif which mediates endocytosis 
through activation of ERK and Src kinases. In addition to this, we previously reported that 
RMKKK motif av syndecan-1 mediates nuclear translocation of syndecan-1 [107-109]. The 
variable region is differing between the four different Syndecans. Syndecan-4 V region 
contains KKXXXKK motif which bind to phosphatidylinositol 4/5-biphosphate and stabilizes 
SDC-4 dimers. Additionally, interaction of this motif with protein kinase C-alpha (PKCα), 
and Rac-1 regulates focal adhesion and migration, respectively [110, 111]. 
Heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS) are linear sulfated 
polysaccharides which are attached covalently to the ED of syndecans via serine residues [89, 
112]. SDC-1/3 carry HS and CS whereas SDC-2/4 carry only HS (Figure 3). GAG’s 
biosynthesis begins with the binding of xylose to serine residues on core protein followed by 
the addition of two galactose (Gal) and a glucuronic acid (GlcA) units. This tetrasaccharide is 
common between HS and CS GAGs [113]. HS synthesizes by adding of a repeating 
disaccharides regions consist of D-glucuronic acid (GlcA) and N-acetyl-glucosamine 
(GlcNAc) to the tetrasaccharide. Whereas in CS addition of N-acetylgalactosamine (GalNAc) 
and D-glucuronic acid (GlcA) is subsequent step [114]. Following synthesis, modification of 
HS initiates by N-deacetylation/N-sulfation of GlcNAc by N-deacetylase/N-sulfotransferase 
(NDST) enzyme. C5-epimerization of GlcA into iduronic acid (IdoA), 2-O-sulfation in the 
C2 position of IdoA and GlcA, and 6-O-sulfation of GlcNAc/GlcNS are other modifications 
of HS [115]. Sulfation of the CS polymer occurs at C4/C6 of GalNAc residues by 
sulfotransferase enzymes [113]. Highly sulfated GAGs regulate different cellular processes 
by interacting with a wide range of proteins [116].    
 
 
Figure 3. Schematic representation of syndecans structure. Syndecans are carrying GAG side chain. 




1.4.3 Shed Syndecans 
Syndecans interact via their HS side chains with many proteins and link the cytoskeleton to 
the ECM. Additionally, it has been shown that this interaction plays role in cell adhesion, 
growth, migration, proliferation, and morphogenesis [97, 102, 118]. Syndecans are bound to 
the cell-membrane, but their ectodomain can be released to the extracellular matrix [119] by 
the action of different.  
Sheddases such as matrix metalloproteinases (MMPs), disintegrin and metalloproteinase 
(ADAMs), at cleavage site that are located at a juxtamembrane site and are common between 
the four SDCs. Matrilysin (MMP-7), MMP-2, MMP-9, MT1-MMP, and MT3-MMP are 
known to cleave SDC-1. Syndecan-2 and Syndecan-4 can be cleaved by MMP-2 and MMP-9 
[120-123]. Syndecans can be cleaved at different site depending on the shaddases. Thrombin, 
and plasmin cleave human SDC-4 at Lys114-Arg115 and Lys129-Val130, respectively [124]. 
The ectodomain Syndecan-1 and 4 can be cleaved by ADAM-7 [125].   
This process is regulated by growth factors, heparanase, trypsin, and cytokines. For example, 
activation of ERK/MAPK signaling pathway by EGF- and thrombin-receptor induces 
Syndecan-1 and 4 shedding [119, 120, 126-130]. Intracellular mechanism such as 
phosphorylation of tyrosine residue on cytoplasmic domain of Syndecans by tyrosine kinases, 
regulates SDC-1 shedding [119, 131].  
The shed extracellular domain of SDC carries its GAG chains as it becomes soluble in the 
extracellular fluid. Thus, the released Syndecans can participate in the same interactions as on 
the cell membrane, and in this way be competitive to their parent molecule. Such solubilized 
SDC-1 can bind to VEGF receptor2 and FGF-2, having a stimulatory effect on growth and 
invasion of tumor cells [132, 133].  
1.4.4 Syndecans in cancer 
 In addition to Syndecans important role in normal homeostasis, they play an important role 
during cancer development and progression. Syndecans act as a co-receptor, at the cell 
surface and as soluble variants in various body fluids, and bind to molecules such as 
cytokines, chemokines, growth factors and extracellular matrix (ECM) components via their 
GAG chains and regulate many cellular processes. In breast carcinomas expression of SDC-1 
correlates with unfavorable prognosis. In addition, SDC-1 regulates tumorigenesis in mouse 
mammary epithelial cells by activating Wnt-1 signaling, and tumor-growth in breast 
carcinoma by activation of fibroblast [134-137]. Furthermore, loss of SDC-1 expression 
increases cell migration and invasion, and differentiation in breast, liver, gastric, lung 
adenocarcinoma, and mesothelioma carcinomas which is in correlates to with unfavorable 
patient’s outcome [138-142].  
Although there were not so many studies regarding the role of SDC-2 in cancer, recent 
studies showed that, overexpression of SDC-2 activates K-ras signaling pathway to induce 
invasive phenotype in pancreatic adenocarcinoma [143]. The same effect was observed in 
breast cancer patients, where the level SDC-2 promoting cells invasion by regulating 
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RhoGTPase [144]. Additionally, SDC-2 is a prognostic factor for head and neck cancer 
[145].  
The loss of receptor protein tyrosine phosphate β/ζ (RPTPβ/ζ) initiate EMT and promoting 
cell migration and invasion in prostate cancer. Loss of RPTPβ/ζ activates Src, Pten, and 
ERK1/2 through activation of pleiotrophin/syndecan-3 activity [146]. In addition, higher 
expression level of SDC-3 is correlated with worse prognosis in pancreatic cancer [147]. 
SDC-4, like other SDCs, interacts with growth factors and regulates several processes 
including cell adhesion, migration, and progression in cancer. Higher expression of SDC-4 is 
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1.5 EXTRACELLULAR VESICLES 
Extracellular vesicles (EVs), comprising apoptotic bodies, microvesicles, and exosomes are 
heterogeneous cell-derived membranous nanoparticles ranging from 30-4000 nm. EVs are 
released from all cells types and can be found in all biological fluids. They have been 
demonstrated to regulate diverse pathological and physiological processes as well as 
intercellular communication. In the beginning, EVs were considered to be cell waste for 
eliminating cell’s unneeded compounds. However, now we know that EVs carry and deliver 
various functional factors such as proteins, lipids, and nucleic acids to specific target cells and 
that this can affect the recipient cell’s activity [149-151].  
1.5.1 Biogenesis and secretion of extracellular vesicles 
Extracellular vesicles classes have different biogenesis mechanisms although all are involved 
in membrane-trafficking processes. 
1.5.1.1 Apoptotic bodies 
Unlike exosomes and microvesicles which are produced by healthy cells, apoptotic bodies are 
released during apoptosis which is a regulated mechanism of cell death. Apoptosis is initiated 
by pyknosis, i.e., irreversible condensation of chromatin, and cell shrinkage. Later, plasma 
membrane blebbing regulated by actin-myosin interactions occurs, followed by disintegration 
of the cellular content into membrane enclosed small vesicles form apoptotic bodies. 
Apoptotic bodies are large (500-4000 nm), contain specific organelles, and nuclear fragments 
[152-154]. 
1.5.1.2 Microvesicles 
Microvesicles are formed by outward vesiculation and fission of vesicles from the plasma 
membrane into the extracellular space. These vesicles are smaller than apoptotic bodies and 
range from 50 to 1000nm in diameter [155, 156]. Microvesicle formation does utilize the 
endosomal machinery and is thus a distinct process from exosome formation. This process is 
depending on the Ras-related GTPase ADP ribosylation factor 6 (ARF 6) and components of 
ESCRT system [157]. Microvesicle budding is initiated with the activation of phospholipase 
D (PLD) by ARF6 which leads to phosphorylation of myosin light-chain kinase (MLCK) by 
ERK. Activation of MLCK triggers the release of microvesicles [155, 158]. 
In addition to the above, endosomal sorting complex required for transport (ESCRT) 
machinery also plays a role in secretion of microvesicles. Interaction of ARRDC1 with 
TSG101 (components of ESCRT system) delocalizes TSG101 to the plasma membrane and 
subsequently results in the secretion of microvesicles which contain these two proteins [157].   
1.5.1.3 Exosomes      
Exosomes are formed during maturation of early endosomes into late endosomes or multi-
vesicular bodies (MVBs). During maturation of early endosome to late endosome, contents 
are sorted into 30-100 nm vesicles via inward budding of the membrane. Late endosomes or 
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MVBs are identifiable by the presence of multiple intraluminal vesicles (ILVs) [159, 160]. 
Protein sorting of ILVs is a highly regulated ESCRT dependent or independent process.  
The first process involves four multi protein complexes of the ESCRT machinery which are 
involved in the ubiquitination of proteins on the inward budding part of the endosomal 
membrane. In the beginning of the process, ESCRT-0 recognizes mono ubiquitinated 
proteins. In the next step, ESCRT-I and ESCRT-II join ESCRT-0 and drive membrane 
budding. Later, ESCRT-III pinch off the membrane to complete the budding process. 
ESCRT-III is recruited to ESCRT-I and II via Alix which can carry and deliver un-
ubiquitinated proteins such as Syndecans and tetraspanin CD63 into the ILVs. Now, ILVs are 
ready to fuse with plasma membrane or be destroyed by the lysosome. Rab27A/B leads ILVs 
toward the cell membrane where the SNARE complex helps them to fuse with membrane. 
Such vesicles released to the extracellular space are called exosomes (Figure 3) [161-165]. 
The second process involves endosome membrane proteins called tetraspanins. Tetraspanins 
consist of four transmembrane domains that are required for protein-protein interaction. ILVs 
form through these protein-protein interaction [166, 167]. Alix, CD9, CD63 and CD81 serve 
as exosome markers.  
 
         
  Figure 3. Exosome biogenesis and secretion. Early endosome (EE) can undergo two pathways either 
transforming to late endosome (LE/MVB) or recycling endosome. Early endosome converts to late endosome by 
packing their proteins content into small intraluminal vesicles (ILVs). Proteins sorting and packing can be 
depending on the ESCRT system. Later, targeted MVBs are ready to fuse their membrane with plasma 
membrane and release the intraluminal vesicles to the extracellular space. These vesicles are called exosome 
now [168].  
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1.5.2 Targeting of recipient cells 
Recently, EVs have gained notable attention as mediators of intercellular communication. 
The released EVs can allow intercellular communication by reaching recipient cells and 
delivering their contents to them. Up-take of the EVs by recipient cells requires docking at 
the cell membrane, activation of cell membrane receptors, and internalization of their cargo. 
The mechanism of these processes is not completely understood and is dependent on the 
origin of the extracellular vesicles and the target cell [169, 170].  
Interaction of EVs with target cells depends on the surface receptors and adhesion molecules 
such as tetraspanins, lipids, extracellular matrix components, integrins, and heparan sulfate 
proteoglycans on both target cells and EVs [171-176].  
After binding to the recipient cell, which depends on the composition and cell membrane 
structure, EVs can either be internalized by endocytosis or remain at the cell membrane. For 
example, the presence of lipid rafts in the cell membrane increase uptake of EVs [177, 178]. 
EVs which remain bound on the cell membrane can be involved in antigen presentation and 
cell signaling. For example, B cell-derived exosomes induce MHC II antigen transfer to T-
cells and stimulates their proliferation [179]. In addition, embryonic stem cells-derived 
microvesicles stimulate trophoblast migration by activation of JNK and FAK signaling 
kinases [180]. On the other hand, EVs can deliver their cargo in the recipient cell after 
internalization which occurs by two mechanisms: via the endocytic pathway or direct fusion 
with the cell membranes. EVs can transport various proteins, lipids, or nucleic acids to 
recipient cells and thus regulate their gene expression [52, 181-183]. 
1.5.3 Extracellular vesicles in cancer  
Extracellular vesicles derived from tumor cells play an important role in tumor progression 
and metastasis by mediating intercellular communication between tumor cells as well as 
between tumor and stromal cells in the niche or at distance. Primary tumor cells require 
active communication with surrounding cells to grow and metastasize. For example, 
Epidermal growth factor receptor variant III (EGFRvIII)-positive glioma cells, secrete 
vesicles bearing EGFRvIII and deliver it to EGFRvIII negative glioma cells in the same 
tumor. EGFRvIII activates MAPK and Akt signaling pathways which leads to recipient cell 
growth [184, 185]. Presence of tetraspanin 8 on the surface of pancreatic cancer-derived 
exosomes induce VEGF-independent angiogenesis in endothelial cell by recruiting other 
proteins such as CD49d and CD106 [172]. 
In the last decade, the effect of EV-borne mRNA and miRNA on recipient cell gene 
expression and fate has attracted attention. Astrocyte-derived EVs containing PTEN-targeting 
miRNA induce invasion and metastasis in brain tumor [181, 186].  
Remodeling of the extracellular matrix during cancer progression induces cancer invasion 
and cell motility. Presence of MMPs in EVs leads to proteolytic degradation of ECM 
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components which in turn promote tumor invasion and angiogenesis [187, 188]. 
Additionally, EVs can also induce EMT in endothelial cells [189]. 
1.5.4 EV’s potential as biomarkers and therapeutic targets  
Tumor-derived EVs contain tumor specific molecules such as RNAs and proteins, which can 
serve as diagnostic biomarkers or therapeutic targets. Thus, EV-associated proteins and 
RNAs can provide information about disease status.  
Epithelial cell adhesion molecule (EpCAM) and CD24 are two tumor derived EVs 
biomarkers. EV-borne CD24 and EpCAM levels were significantly higher in patients with 
ovarian cancer when compared with benign and healthy controls [190, 191]. Additionally, 
exosomal integrins can predict organ-specific metastasis. For example, exosomal integrins 
αvβ5 and α6β4/α6β1 were associated with liver and lung cancer, respectively [176].  
Exosomal genetic material, including DNA, RNA, mRNA, and miRNA, can be used as 
diagnostic and/or prognostic biomarkers. Exosomal miRNA-17-92a cluster and 
miRNA141/miRNA375 are significantly higher in colorectal cancer and prostate cancer, 
respectively [192-194]. 
Due to tumor derived EVs capacity to transform healthy cells to cancer cells, tumor derived 
EVs have been considered as a new target for cancer treatment. EVs biogenesis, content, and 
surface protein composition can serve as a target in cancer therapy. Rab27, which is involved 
in exosomes production, knockdown reduce exosome production, tumor growth and 
metastasis in metastatic melanoma [195-197].    
  





 THESIS BACKGROUND 
Syndecan-1 is a differentiation marker structurally corresponding to a single type I 
transmembrane proteoglycans (PGs) with an N-terminal signal peptide, an extracellular 
ectodomain carrying glycosaminoglycan (GAG) side chains, a single hydrophobic 
transmembrane domain, and a short C-terminal cytoplasmic domain [198, 199]. Syndecan-1 
exhibits a characteristic pattern of cell- and development-specific expression and a complex 
regulation both on transcriptional and post-translational level. It is proposed as “fine tuner of 
cellular signaling”, as it plays critical roles for differentiation, proliferation, wound healing, 
migration, and angiogenesis in various pathological conditions [103, 200, 201]. The HS 
chains of syndecan-1 contain defined short sequences that specifically bind growth factors to 
their respective receptors, necessary for the receptor function. On the cell membrane the 
Syndecans are turned over within a few hours through proteolytic cleavage and shedding of 
most of the ectodomain as an intact fragment which instantly converts the membrane-bound 
ectodomain into soluble effector, which in turn may act as agonists or antagonists that 
regulate the effect of the cognate growth factor receptor [199]. This shedding might constitute 
one important contributing factor to decreased cell-surface syndecan-1 level, adverse 
prognosis, and increased therapy resistance of tum ours such as malignant mesothelioma. 
Syndecan-1 is expressed in epithelial cells in a temporo-spatial manner [202] and it is down-
regulated in dedifferentiated tumor components and mesenchymal tumors [203]. Very few 
previous studies have addressed the regulation of syndecan-1 in mesenchymal cells, or the 
importance of the respective functional domains of this PG in angiogenesis. Syndecan-1 may 
serve as a prognostic marker probably depending on whether syndecan-1 is cell bound or 
shed to the stroma. We aim to further characterize the functional domains of syndecan-1 and 
evaluate the role of this protein in pleural effusions. 
Traditionally syndecan-1 is associated with functions at the level of the cell membrane, where 
it binds and activates several different growth factors (GF) – growth factor receptor (GFR) 
complexes, thus acting as a co-receptor in signalling [199, 200]. We have, however, 
previously shown a substantial proportion of syndecan-1 at intracellular locations and 
preliminary data point toward involvement in regulating angiogenesis [204].  
Syndecan-1 acts as a co-receptor for a wide range of extracellular ligands, including VEGF, a 
key signaling molecule in angiogenesis both during embryogenesis and tumor growth [205-
211]. SDC-1 regulates angiogenesis by interacting with integrins and insulin-like growth 
factor-1(IGF-1R) receptor. Upon activation a ternary receptor complex is formed on tumor 
cells and activated endothelial cells undergoing angiogenesis, that activates intracellular 
integrin signaling. In addition, there is a unique sequence on the Syndecan-1 extracellular 
domain, known as synstatin, which inactivates the integrin/IGF-1R/ Syndecan-1 complex and 
consequently the signaling pathways involved in angiogenesis. This angiogenesis modulating 
potential of syndecan-1 may very well serve as a therapeutic approach [212].  
The mesenchymal cells we use as model display an inherited biphasic phenotype. Presence 
of syndecan-1 on the surface of malignant mesothelioma cells is associated with favourable 
prognosis, whereas the decrease of syndecan-1 deteriorates the prognosis, suggesting a role 
as prognostic factor. This effect, however, seems to depend on whether syndecan-1 is tumor 
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cell derived, cell-surface associated, shed or synthesized by the tumor stroma. Furthermore 
syndecan-1 might sequester soluble factors regulating angiogenesis and thereby modulate 
their local concentration, leading to altered angiogenesis. Experimental data also suggest 
that the shed syndecan-1 might be involved in therapy resistance through an EGFR 
regulated mechanism. 
Our recent studies show that restoration of syndecan-1 hampers the proliferation [213] cell 
cycle progression and migration of mesenchymal cells. Subsequent pathway analysis 
indicates the involvement of many possible mediators including a critical role for several 
tyrosine kinase receptor mediated pathways and TGB-β [210]. 
The sulphation pattern of HS chains is regulated by several enzymes and has a crucial role 
in their interactions with the signaling molecules. One of these enzymes acting at the cell 
surface is sulfatase-1 (SULF1), an endosulfatase, catalyzing selective removal of 6-O sulfate 
groups from S domains of heparan sulfate chains, highly regulating the GF binding and by 
this, a multitude of signaling pathways. Data suggest that SULF1 could be a TGFβ responsive 
gene [214, 215]. Syndecan-1 on the other hand can function as a negative regulator of TGFβ 
signaling. Our data suggest that syndecan-1 has complex interactions with TGFβ mediated 
signaling, and that deregulation of SULF-1 could potentiate the effects of syndecan-1. The 
interaction between Syndecan-1, TGFβ and SULF-1 may constitute an interesting loop of co-





 RESEARCH AIMS 
There are two major aims of this thesis. The first general aim was to investigate the role of 
SDC-1 in the angiogenesis of mesenchymal cells and epithelial to mesenchymal transition 
and the second was to study the diagnostic and prognostic utility of syndecan-1 in 
combination with novel and established biomarkers. The specific aims of this thesis work 
were as follows: 
Specific aims 
Paper I: To investigate the role of syndecan-1 in angiogenesis of mesenchymal cells. How 
does syndecan-1 influence angiogenesis? 
Paper II: Does modulation of syndecan-1 expression influence the TGF-β induced epithelial-
mesenchymal transition. 
Paper III: To evaluate soluble (shed) syndecan-1 and angiogenic-related factors as possible 
diagnostic and prognostic biomarkers. 
Paper IV: To characterize the different extracellular vesicle populations in pleural effusions. 




 MATERIALS AND METHODS 
4.1 CELL LINES 
In this thesis work we used A human malignant mesothelioma cell line, STAV-AB with 
epithelial-like morphology (paper I), and a fibrosarcoma cell line, B6FS with fibroblast-like 
morphology (paper II), one human lung adenocarcinoma cell line, A549 with epithelial-like 
morphology (paper II), and the human umbilical vein endothelial cells (HUVECs, paper I).  
STAV-AB cells were established from pleural effusion while B6FS cells were from poorly 
differentiated fibrosarcoma. A549 and HUVEC cells were obtained from ATCC.  
STAV-AB and B6FS cells have originally low endogenous SDC-1 expression level. SDC-1 
was overexpressed in these cells by stable transfection with a plasmid vector carrying the 
human full-length SDC-1 gene (FL) or with the same vector lacking SDC-1 gene (EV) as a 
negative control [213]. Cells overexpressing SDC-1 were selected by Geneticin. STAV-AB 
overexpressing SDC-1 cells have been used to study the effect of SDC-1 on angiogenesis of 
HUVEC cells.  
B6FS cells (no SDC-1 expression) were transfected with the same vectors carrying human 
full-length SDC-1 gene (FL) and (EV), as well as a truncated variant lacking RMKKK 
peptide responsible for nuclear translocation of SDC-1 (RMKKKdel). B6FS cells transfected 
with the above constructs have been used to study the effect of nuclear translocation of SDC-
1 on EMT. 
4.2 PLEURAL EFFUSIONS 
Pleural effusions from patient with malignant pleural mesothelioma, metastatic lung 
adenocarcinoma and benign conditions were collected and diagnosed at the Department of 
Pathology and Cytology, Karolinska University Hospital at Huddinge, Sweden and at the 
Department of Chest Disease, Medical Faculty of Eskisehir, Turkey (paper I, III, and IV). 
Pleural effusions from Sweden were further verified by extensive immunocytochemistry and 
biomarker analyses including Hyaluronan and Mesothelin. All samples from both Sweden 
and Turkey were collected before any treatment was given. The study was approved by the 
ethical review board of Stockholm, Sweden (2009/1138-31/3 and 2007/1089-32) and the 
ethical review board of Eskisehir University, Turkey. Pleural effusion was used to study 
diagnostic/prognostic biomarkers and extracellular vesicles characterization (paper III and 
IV). 
4.2.1 Extracellular vesicles fractionation 
All pleural effusions (paper IV) were collected and diagnosed at the Department of Pathology 
and Cytology, Karolinska University Hospital. Samples were centrifuged at 300g for 10 
minutes to discard cell debris (C), 2000g for 10 minutes to isolate apoptotic bodies (AB), 
10000g for 10 minutes to isolate microvesicles (MV), 100 000g for 90 minutes to isolate 
exosomes (EX). Additionally, dissolved free proteins in the supernatant (SP) remained from 
last centrifugation step (100 000g), were concentrated. 
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4.2.2 Nanoparticle tracking analysis (NTA)  
To determined exosomes size and concentration, nanoparticle tracking analysis (NTA) 
(NanoSight Techniques) was used (paper IV). Nanoparticle analysis is based on the 
Brownian motion and characterizing nanoparticles from 10 nm – 1000 nm in solution. The 
system introduces a laser beam to the samples through a glass prism which illuminates the 
particles. Particles are visualized by optical microscope fitted with video camera. NTA 
software identifies particles size and concentration.    
4.3 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
To measure SDC-1 expression level in SDC-1 overexpressed cells (STAV-AB and B6FS) 
prior each experiment (paper I and II), we used FACS. Cells were stained with primary anti-
body against SDC-1 (1:20 dilution, MCA2459, Bio-Rad Laboratories, Solna, Sweden) for 30 
min on ice, and secondary antibody Alexa 488-conjucated goat anti mouse (A-110017; 
Invitrogen/Thermo Fisher Scientific) for 15 min in dark. Becton Dickinson Flow cytometry 
(Mountain View, CA, USA) was used to identify fluorescence intensity. 
4.4 BEAD-BASED MULTIPLEX EXOSOME FLOW CYTOMETRY ASSAY  
To characterize surface markers of different fractions derived from pleural effusion, we used 
MACSPlex assay coupled by flow cytometry (paper IV). We used commercial kit 
(MACSPlex Exosome kit, human, Miltenyi Biotec) which comprises a cocktail of various 
fluorescently labelled bead populations which coated with a specific antibody, and detection 
reagents. The kit allows detection of 37 exosomal surface epitopes plus two isotype controls. 
Samples surface epitope bind to the antibody and be detected by different fluorescence 
intensities by flow cytometry. 
4.5 PROTEOME PROFILER ARRAY 
To determine expression level of multiple angiogenesis-related proteins (paper I), we used 
Proteome Profiller Human Aniogenesis Antibody Array (R&D Systems, Inc., Minneapolis, 
MN, USA) kit. Proteome profiler array is a membrane-based immunoassay which the 
membrane is coated with capture antibodies against specific proteins. A mixture of sample 
with a cocktail of biotinylated detection antibodies was added to the membrane. 
Chemiluminescent detection reagents were used to visualized targeted proteins. 
4.6 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
To measure SDC-1, VEGF and Mesothelin level in cell lysate, supernatant (SDC-1) and 
pleural effusion (SDC-1, VEGF and Mesothelin), ELISA was used (paper I and III). We used 
commercial kits (human CD138/SDC-1; Gen-Probe Diaclone, France, cat. No. 950.640.192, 
human VEGF; Quantikine ELISA, R&D systems, Minneapolis, MN, USA, cat. No. DVE00, 
and human N-ERC/mesothelin Assay kit, IBL) for all three antigens of interest. ELISA is a 
sensitive assay and is based on a capture antibody coated onto a plate surface. The antibody 
 
 23 
binds to the relevant antigen in the sample, can be detected by labelled secondary antibody, 
and quantified by reading absorption in a spectrophotometer. 
4.7 LUMINEX ASSAY 
To assess the level of different biomarkers simultaneously, Luminex bead-based 
immunoassay was used (paper I, III, and IV). We measured SDC-1 level in SDC-1 silenced-
cells (paper I), and 10 different biomarkers, including angiopoietin-1, galectin-1, osteopontin, 
mesothelin, HGF, VEGF, NRG1-β1, TIMP-1, MMP-7, and SDC-1, level in pleural effusion 
(paper III) and exosomes isolated from pleural effusion (paper IV) by using Human premixed 
multi-analyte Luminex kit (cat: LXSAHM). 
Analytes specific antibodies, coupled to bead region with fluorophores at set ratio for each 
unique bead region, were incubated with sample. Subsequently, samples were incubated with 
a mixture of biotinylated detection and streptavidin-phycoerythrin (PE) reporter antibodies. 
Beads were illuminated by two spectrally distinct light emitting diodes (LEDs), one to 
determine beads region and the second to determine the PE-derived signal which is 
proportional to the amount of analyte bound. The median fluorescence intensities were 
determined on a Luminx® 100/200 analyzer. 
4.8 IMMUNOFLUORESCENCE ANALYSIS  
To measure the subcellular localization of SDC-1, epithelial cell markers (E-cadherin and 
CAR), and mesenchymal cell markers (vimentin and ZEB-1) in lung adenocarcinoma cell 
line (A549), immunofluorescence (IF) staining, was used (paper II). Primary antibody 
staining was performed overnight at 4°c with following antibodies: anti-SDC 1 (Abcam, 
ab128936, rabbit) 1:500, anti-Ecad (Cell Signaling, 3195S, rabbit) 1:500, anti-CXADR 
(SIV), rabbit, 1:10, anti-Vimentin (HPA027524, Sigma-Aldrich, Stockholm, Sweden, rabbit) 
1:50, and anti-Zeb1 (HPA027524, Sigma, Aldrich, rabbit) 1:50. Secondary antibody staining 
was performed for 1 hour at room temperature using Alexa Fluor 488 goat anti-rabbit 
(A32731, Thermo Fisher Scientific). immunofluorescent staining was localized to cell 
surfaces (E-cadherin, CAR, vimentin, and ZEB-1) and to the nucleus (SDC-1).  
4.9 IMMUNOBLOT ANALYSIS 
To determine levels of E-cadherin, N-cadherin, vimentin, and SDC-1 (paper II) and identify 
differential centrifugation fractions specific proteins (paper IV), western blot was used. 
Protein concentration were determined with BCA assay (Bio-Rad) using bovine serum 
albumin as standard. The following primary antibodies were used: rabbit polyclonal antibody 
against E-cadherin (Cell Signaling, Leiden, The Netherlands, 1:1000), N-cadherin (Cell 
Signaling, 1:1000), vimentin (Cell Signaling, 1:1000), SDC-1 (Abcam, Cambridge, UK, 
1:1000) in the second paper, and CD9 (Abcam ab-92726, 1:2000), cleaved caspase 9 (Cell 
Signaling 9505S, 1:1000), CD81 (Santa Cruz sc-9158, 1:200) in the fourth paper. Freshly 
prepared secondary antibodies (Donkey Anti-Rabbit or Sheep Anti-Mouse IgG F(ab´)2 
Fragment Specific, Peroxidase conjugated, Thermo Fisher) and (Li-Cor 926-68020, 926-152 
 
24 
68071, 926-68079, 1:15000) were used in paper II and paper IV, respectively. In this 
technique proteins are separated based on their weight through gel electrophoresis and 
detected by anti-body against to the protein of interest.  
4.10 GENE SILENCING  
To reduce the expression level of SDC-1 (paper I and II) and MMP-7 (paper I) genes, 
transient knockdown by small interfering RNA (siRNA) was used. A cocktail of three siRNA 
(SDC-1 silencer pre-designed siRNA, s12632, s12633, and s12634, Ambion/Thermo Fisher 
Scientific) constructs was used to silence SDC-1 and a scrambled siRNA, with no target 
mRNA, was used as a negative control. SDC-1 expression level was validated on mRNA 
level by qPCR. We used High Pure RNA Isolation kit (Roche, Mannheim, Germany) for total 
RNA isolation and cDNA synthesis was performed using First Strand cDNA Synthesis kit 
(Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England). 
The qPCR was performed with Platinum® SybrGreen qPCR SuperMix-UDG kit (Invitrogen) 
with the following set of sense/antisense primer (CyberGene AB, Sweden) sequences: SDC-1 
fwd: TCT GAC AAC TTC TCC GGC TC and SDC-1 rev: CCA CTT CTG GCA GGA CTA 
CA and GAPDH fwd: ACA TCA TCC CTG CCT CTA CTG G and GAPDH rev: AGT 
GGG TGT CGC TGT TGA AGT C.    
Same procedure was used to reduce the expression level of MMP-7 gene with the difference 
that we used one siRNA construct (Cat. No.sc-41553, Santa Cruz Biotechnology, Inc, Dallas, 
TX, USA). Scrambled siRNA with nonsense sequence was used as a negative control. qPCR 
was performed as it described above with the following set of sense/antisense primers which 
were designed by us: MMP-7 fwd: GAG TGC CAG ATG TTG CAG AA and MMP-7 rev: 
AAA TGC AGG GGG ATC TCT TT, and GAPDH fwd: ACA TCA TCC CTG CCT CTA 
CTG G and GAPDH rev: AGT GGG TGT CGC TGT TGA AGT C.   
4.11 CELL PROLIFERATION ASSAY 
To study the effect of SDC-1 overexpression on the proliferation of HUVEC cells (paper I), 
the WST-1 assay was used. HUVEC cells proliferation was assessed by Cell Proliferation 
Reagent WST-1 (Roche Diagnostics Scandinavia AB, Bromma, Sweden). The HUVEC cells 
were treated with conditioned medium from SDC-1 overexpressing mesothelioma cells. Their 
proliferation was assessed by the WST-1 reagent. Anionic tetrazolium salt (WST-1) requires 
an electron coupling reagent to be cleaved (formazan) and permeates into the cytosol of 
metabolically active cells. This process is depending on dehydrogenase enzyme activity. 
Presence of active dehydrogenase enzyme reduces this process. Thus, the amount of 
formazan dye formed correlates to the number of metabolically active cells. Optical densities 
were quantitated with a spectrophotometer.   
4.12 CHEMOTOAXIS ASSAY 
To investigate the effect of SDC-1 on the chemotactic capability of HUVEC cells, Transwell 
migration assay with a pore size of 3µm (Transwell chamber, Corning, NY, USA) was used 
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(paper I). HUVEC cells were seeded in the upper chamber and conditioned medium from 
SDC-1 overexpressing and control cells were added to the lower chamber. To initiate cell 
movement across the membrane, recombinant VEGF (10 ng/ml) was added to the 
conditioned medium. After 24 hours incubation time, the membrane between the two 
compartments was fixed in 4% formaldehyde and cells were stained with 0.2% crystal violet. 
The percentage of area covered by migrated cells to the underside of the membrane was 
determined. 
4.13 INVASION ASSAY  
To study the effect of nuclear SDC-1 in SDC-1 overexpressing cells on the invasive behavior 
of B6FS cells, Invasion assay was used (paper II). The assay was performed by using 8µm 
pore cell culture inserts (Merk Chemicals and Life Science, Stockholm) and 3mm cylinder. 
This assay is based on the cell migration capacity towards chemoattractants. B6FS cells 
overexpressing SDC-1 (FL, RMKKK deleted, and control) were seeded on top of growth 
factor-reduced Matrigel (3mg/ml, AH Diagnostics) into the cell culture insert. The insert was 
suspended over a larger well which contained medium (control), or medium + TGF-β 
(10ng/ml). Migrated cells to the lower insert were counted using Alamar blue and Countess 
(Invitrogen/Thermo Fisher Scientific).  
4.14 WOUND HEALING ASSAY  
To further study the effect of SDC-1 overexpression on the HUVEC cells migration and 
proliferation rate, wound healing assay was used (paper I). We used CELL BIOLABS 
CytoSelect 24-well wound healing assay kit. The wound field (0.9 mm) was created by a 
standardized plastic insert and the HUVEC cells were cultured till they formed a confluent 
monolayer. At this point, the insert was removed, and HUVEC cells culture medium replaced 
was with the conditioned medium from SDC-1 overexpressing and SDC-1 silenced 
mesothelioma cells. Relevant controls were used for each condition. The closure of the 
wound was measured at different time points (0, 4, 8, and 24 hours) and the area was 
measured with ImageJ software. 
4.15 TUBE FORMATION ASSAY 
Tube formation assay is a widely used in vitro assay to study angiogenesis. It is based on the 
reassembling and establishing new cell-cell contacts to form new vessel lumen. To study the 
effect of SDC-1 overexpression on the tubulogenesis of the HUVEC cells, we performed this 
tube formation assay (paper I). HUVEC cells were seeded on extracellular matrix gel (ECM 
gel, Cell Biolabs, San Diego, CA, USA), and treated with the conditioned medium from 
SDC-1 overexpressing cells, SDC-1 silenced cells, and their relevant controls with a ratio of 
1:2 conditioned medium/HUVEC complete medium (vol/vol). Cells were incubated for 6 
hours in conditioned medium and then tube formation was monitored. Quantification 
performed using image processing software to measure the tube area, the length and/or 
number of branch points, and total number of tubes. 
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4.16 STATISTICAL METHODS 
All statistical analysis in were performed using GraphPad software. The level of significance 
was less than 0.05 (p<0.05). 
4.16.1 Kaplan-Meier Survival analysis 
To investigate the correlation of different biomarker levels with the survival of malignant 
mesothelioma patients, Kaplan-Meier survival curves were constructed (paper I and III). 
Cutoff Finder was used to determine a cut-off value for each biomarker based on the most 
significant and highest hazard ratio.  
4.16.2 Receiver Operating characteristic (ROC) analysis 
To assess the diagnostic efficiency of individual biomarkers (paper III), ROC analysis was 
used. In general, ROC curve shows the trade-off between the sensitivity and the specificity of 
a classifier. The area under the ROC curve (AUC), which ranges between 0.5-1, shows how 
good a classifier is. AUC values exceeding 0.7 indicates possible diagnostic value of the 
classifier. 
4.16.3 Logistic Regression  
To develop a model for identifying and combine diagnostic biomarkers for diagnosis (paper 
III), logistic regression was used. Logistic regression tests the potential association between 
multiple exposure variables (X) with an outcome variable (Y) which is obtained by Odds 
ratio (OR). Odds ratio shows the association between an exposure and an outcome. Odds 
ratio ranges between zero and infinity where 1 shows that there is no difference between 
studied variants.     
 
   
    
    
 
  
     






A little progress each day, adds up to big results. 
Paper I: Syndecan-1 overexpressing mesothelioma cells inhibit proliferation, wound 
healing, and tube formation of endothelial cells 
Angiogenesis is an important process in aggressive tumors like MM. In this paper we studied 
the role of syndecan-1 (SDC-1) overexpression on angiogenesis. The first hypothesis was to 
study the effect of SDC-1 overexpression on the secretion of angiogenesis-related proteins. 
The result of this analysis showed that, several angiogenesis-related proteins were 
significantly altered by SDC-1 overexpression and silencing including, FGF-4, NRG1-β1, 
TGF-β1, HGF (were significantly up-regulated) angiopoietin-1, TIMP-1, and TSP-1 (were 
significantly down-regulated) upon syndecan-1 overexpression, and IL-8 (was significantly 
up-regulated) upon SDC-1 silencing. After profiling the angiogenesis-related proteins 
affected by overexpression, we studied the effect of these proteins on the proliferation, 
migration, and tube formation of endothelial cells. 
The conditioned medium from SDC-1 overexpressing MM cells, acted inhibitory on all these 
function, while conditioned medium from SDC-1 silenced MM cells, increased the ability of 
endothelial cells to migrate while there was no effect on tubulogenesis. The inhibitory effect 
of SDC-1 seemed to be regulated through angiogenic proteins. 
Furthermore, there was a significant positive correlation between shed SDC-1 and VEGF in 
pleural effusion from MM patients. In addition to this, VEGF turned out to be of prognostic 
value in MM patients. 
Paper II: Nuclear syndecan-1 regulates epithelial-mesenchymal plasticity in tumor cells 
One main cause of death in cancer is related to the formation of metastases. Epithelial-
mesenchymal transition (EMT) give the malignant cells invasive and metastatic properties. 
SDC-1 is mainly expressed in epithelial cells and is deregulated during EMT. In this study, 
we investigated the possible role of nuclear SDC-1 in EMT in tumor cells. 
Nuclear SDC-1 was knocked down by interfering RNA in A549 cells, which gave more 
mesenchymal morphology to these cells. Simultaneously, the E-cadherin level was 
significantly reduced compared to the scrambled control cells. This loss was complete after 
exposure to TGF-β. In addition to this, the N-cadherin level was unaffected by SDC-1 
knockdown but significantly increased after TGF-β treatment. 
When validated by immunofluorescence staining, E-cadherin and CAR were lost in both 
SDC-1 knockdown A549 cells and control cells after TGF-β treatment. Moreover, vimentin 
and Zeb1 were more expressed in SDC-1 knockdown compared to the control cells after 
TGF-β treatment.   
Paper III: Multiplex soluble biomarker analysis from pleural effusion 
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The diagnosis of MM can be based on the examination of cytological or histological 
materials. Whatever the diagnostic material used, the diagnosis is a challenge. Analyses of 
soluble biomarkers in the effusion can in some cases provide help. A diagnostic battery 
would, however, gain if additional markers could be added. SDC-1 plays dynamic roles in 
different cancers and in the pleura, it is shed into the effusion together with angiogenesis-
related proteins studied in paper I. Using the Luminex assay several of these compounds 
seemed to give diagnostic information, distinguishing MPM, metastatic adenocarcinoma and 
benign mesothelial proliferations.  
Thus galectin-1, mesothelin, osteopontin, shed SDC-1, VEGF, MMP-7, HGF, and TIMP-1 
had significantly higher level, and NRG1-β1 had significantly lower level in MPM patients 
compared with the benign conditions. As indicated by ROC curve analyses galectin-1, 
mesothelin, osteopontin, NRG1-β1, and shed SDC-1 all were of high diagnostic value in 
MPM patients.  
In addition, patients with MPM and metastatic adenocarcinoma could be distinguished using 
galectin-1, mesothelin, MMP-7, and shed SDC-1. Galectin-1 and mesothelin had significantly 
higher level whereas MMP-7 and shed SDC-1 had significantly lower level in MPM effusion 
compared with metastatic adenocarcinoma patients. Moreover, stepwise logistic regression 
analysis showed that MMP-7, mesothelin, and osteopontin had higher predictive value for 
distinguishing MPM from adenocarcinoma. 
We could also demonstrate that the level of shed SDC-1 in MPM patients correlated 
positively with the levels of HGF and NRG1-β1.   
Furthermore, the levels of shed SDC-1 and VEGF have prognostic value in MPM patients 
which was in accordance with our previous result (paper I). High level of these two 
compounds had significantly worse prognosis. 
Measuring the concentration of these nine compounds can be useful in useful adjuncts in 
effusion cytology, more often allowing a definite diagnosis based on the first diagnostic 
material available. 
Paper IV: Characterization of different extracellular vesicle populations present in the 
pleural effusion 
Tumor micro-environment is a dynamic regulator of tumor development, progression, and 
metastases. Extracellular vesicles including, apoptotic bodies, microvesicles, and exosomes, 
are nanoparticles released from cells specially cancer cells. These particles bear functional 
molecules and can be taken-up by target cells which highlight their importance as cell-to-cell 
mediators. In this study we isolated and characterized extracellular vesicles derived from 
pleural effusion from patients with malignant pleural mesothelioma (MPM) or metastatic 
adenocarcinoma (AD), and from patients with benign (BE) conditions. 
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Extracellular vesicles (apoptotic bodies, microvesicles, and exosomes) were isolated from 
pleural effusions using differential ultra-centrifugation. To validate differential the ultra-
centrifugation fractions, we detected CD81 in the microvesicles and exosomes, and cleaved 
caspase 9 in the protein lysate of the apoptotic bodies.  
The concentration and size distribution of the exosomes was in accordance with previous 
studies and the concentration of exosomes varied between individuals. The surface markers 
CD2, CD8, CD9, CD24, CD44, CD81, CD105, CD133, CD146, MCSP, and ROR1 were 
elevated while CD40, CD45, and CD49e had lower levels on the exosomes compared to 
apoptotic bodies and microvesicles.  
All studied angiogenesis-related proteins were present in the extracellular vesicles derived 
from pleural effusion of MPM, AD, and benign conditions. In addition to this, the level of 
galectin-1, mesothelin, osteopontin, VEGF, MMP-7, HGF and NRG1-β1 were significantly 
lower in exosomes compared with supernatant whereas, there were no significant differences 
in the level of angiopoietin-1, TIMP-1, and shed SDC-1.  
Angiopoietin-1 and TIMP-1 seemed to be preferably transported in exosomes while the other 
factors mainly presented in supernatant as soluble molecules. Most importantly galectin- 1, 
osteopontin, mesothelin, and VEGF had higher level whereas SDC-1 and HGF had lower 
level in exosomes derived from MPM patients compared to patients with AD and benign 







The aim of argument, or of discussion, should not be victory, but progress. 
                                                                                                        Joseph Joubert  
Angiogenesis, neoformation of new vascular networks, is an important feature of solid 
tumors since it is required for tumor growth and metastasis. Pro- and anti-angiogenic proteins 
are produced during angiogenesis. The phenotypic switch in tumor cells is the result of a 
balance between pro- and anti-angiogenic regulators. Vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), and transforming growth factor (TGF-β) are 
important angiogenesis regulators in tumors [78, 205, 216]. Importantly, increased 
vascularity is associated with poor prognosis and advanced tumor stage [207, 217]. 
Syndecan-1, a transmembrane proteoglycan, acts as a co-receptor for several extracellular 
ligands and regulates various cellular processes including angiogenesis [218-220]. 
Membrane-bound SDC-1 is released to ECM by shaddases resulting of a free SDC-1 
ectodomain which contain HS chain and is active [221]. Hence, we aim to study the role of 
SDC-1 in malignant pleural mesothelioma angiogenesis. 
In this study, we showed that angiopoietin-1, thrombospondin-1 (TSP-1), and tissue inhibitor 
of metalloproteinases-1 (TIMP-1), among other angiogenesis-related proteins, were 
significantly down-regulated upon SDC-1 overexpression, whereas IL-8 was significantly up-
regulated upon SDC-1 silencing. In addition to this, TIMP-1, and TSP-1, among other 
proteins which were altered by both SDC-1 overexpressing and silencing, were significantly 
up-regulated upon SDC-1 silencing.  
Previous studies showed that activation of Tie-2 receptor tyrosine kinase by angiopoietin-1 
play key roles in endothelial cell vascularization by increasing level of TJ-associated proteins 
(ZO-1, occludin, and claudin-5) [222, 223]. TSP-1 is known as both anti-angiogenic and 
immunomodulatory factor which regulates various cellular processes including migration, 
proliferation, cell adhesion, extracellular matrix organization, and growth factor activity [224-
226]. Additionally, TSP-1 can activates TGF-β which is an important regulator of 
angiogenesis [227]. Furthermore, TIMP-1 acts as an anti-angiogenic factor through 
downregulation of MMP-1 and inhibition of endothelial cells migration [228].  
Moreover, up-regulation of pro-angiogenic factors including, FGF-4 [229, 230], HGF [231, 
232], NRG1-β1 [233], had no significant effect on HUVEC cells proliferation, migration, and 
tube formation in our system. This might be due to a stronger effect of anti-angiogenic 
factors.  
VEGF is a key regulator of angiogenesis. It has been shown that several growth factors, 
including FGF, TGF-β, EGF, and TNF, and hypoxia induce VEGF expression [234, 235]. In 
addition, VEGF level is significantly correlated with tumor angiogenesis and metastasis in 
many cancers including MPM [236-240]. Shed SDC-1 level is associated with cancer 
chemotherapy resistance, progression, and prognosis [221, 241]. We previously showed that 
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mesothelioma patients with lower level of shed SDC-1 had a longer survival [242]. In this 
study we showed that there is positive correlation between shed SDC-1 and VEGF.  
Taken together, our data demonstrate an anti-angiogenic effect of SDC-1 on HUVEC cells 
regulated by an array of anti- and pro- angiogenesis-related factors. Moreover, shed SDC-1 
could be a prognostic indicator in MPM.   
Another feature of importance for a malignant tumor is the epithelial-mesenchymal transition 
(EMT). This is a process in which epithelial cells increase their motility and invasiveness by 
acquiring more mesenchymal phenotypes. Previous studies have shown that this process can 
be induced in different ways by extracellular signals, involving factors such as hepatocyte 
growth factor (HGF), tumor necrosis factor-α (TNF-α), and transforming growth factor-β 
(TGF-β) plays an important role in this process. 
SDC-1 knockdown repressed E-cadherin, induced N-cadherin, and increased nuclear Zeb1 in 
human lung adenocarcinoma cell lines (A549). In addition, SDC-1 overexpression decreased 
the level of N-cadherin and vimentin in fibrosarcoma (B6FS) cells. We previously showed 
that overexpression of SDC-1 enhanced cell adhesion and inhibit cell migration in 
fibrosarcoma cells (B6FS) [243]. Furthermore, we showed that overexpression of SDC-1 
down-regulates TGF-β in MM cells [210]. Taken together, these data suggest the role of 
SDC-1 in EMT.  
The diagnosis of MPM and distinguishing it from metastatic adenocarcinoma and benign 
conditions is challenging. The search for new diagnostic biomarkers is therefore essential. 
While hyaluronan and mesothelin can be used in clinical practice [43], previous studies has 
indicated that other factors such as osteopontin and fibulin-3 can be valuable [17, 35, 244-
246].  
In addition, TGF-β level is higher in MPM effusions compared to those in lung 
adenocarcinoma patients [247, 248]. In our multi-parameter test it could be shown that 
galectin-1, NRG1-β1, shed SDC-1, VEGF, and TIMP-1 also had good diagnostic efficiency 
in MPM patients. The shed SDC-1 level positively correlated with VEGF level in MM (paper 
I). These two factors correlated in this material to shorter overall survival, and these factors 
may thus also be of prognostic value.  
None of these new possible factors have sufficient specificity to motivate their use as single 
biomarkers in diagnostic routine. A diagnostic battery must therefore be based on many 
biomarkers. Multivariate tests like the Luminex used here could be the basis for such 
analysis. The evaluation of such multiparameter test, however, needs a logistic model, which 
can be deduced using larger patient materials. 
The diagnosis of a malignant condition in the pleura – primary MPM or metastatic 
adenocarcinoma – is a diagnosis if an advanced condition. Earlier diagnosis of MPM may 
improve the therapeutic options, but this must then be obtained before the effusion is 
established. One possibility could be pre-symptomatic analysis of serum from persons at risk 
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(asbestos or erionite exposed individuals). For such a future option the appearance of these 
factors in blood must be clarified.  
Release EVs into the extracellular space are important mediators of cell-to-cell 
communication and a way for the malignant cell to interact with its surroundings. The tumor 
cells can induce physiological and pathological changes in recipient cells by delivering the 
cargo of active proteins and RNA. When EVs are released from pleural tissues, they will also 
end up in the effusion. The size of vesicles in the exosome fraction was in accordance with 
previous studies [249]. Their concentration in the effusion depends on several factors such as 
their rate of biogenesis (tumor burden, number of inflammatory cells) and the volume 
depending on rate by which the fluid is accumulated. It is therefore natural that their amounts 
varied between the effusions, also when thoracocentesis had been repeated. 
The exosomes present in the effusion may have been produced by any of the cells present. 
Characterization of EVs surface markers is a way to mirror their cellular origin [250]. Such 
factors are CD2, CD8 (T-cells), CD9, CD81 (tetraspanin family), CD24 (B-lymphocytes), 
CD44 (large number of mammalian cells), CD133 (malignant cells), CD105, CD146 
(endothelial cells), MCSP (epidermal stem cells) and ROR1 (cancer cells). These factors 
were all more abundant in the exosome fraction compared to microvesicles and apoptotic 
bodies. These results indicate that the origin of exosomes present varied. Specific analyses of 
tumor exosomes should be possible using immunoprecipitation with factors such as CD133.  
Still the content of exosomes was different in the malignant effusions, indicating origin in 
tumor cells. The exosomes isolated from MPM effusions had higher level of mesothelin, 
osteopontin, galectin 1, and VEGF compared to those in AD and benign effusions. Due to the 
ability of EVs in mediating cell-to-cell communication, these biologically active proteins can 
be delivered to other cells, a way for the MM cells to regulate the recipient cells signaling 
pathways [161, 251]. For example, activation of PI3K/Akt and MAPK/ERK signaling 
pathways by mesothelin inhibit apoptosis. In addition, mesothelin can increase cell 
proliferation and invasion by activating STAT3 signaling pathway and interacting with 
CA125 proteoglycan, respectively [252, 253]. 
Similarly, the pleural effusions from AD patients had higher exosome levels of SDC-1 and 
HGF compared to MPM and benign effusions. Previous studies have shown that EVs cargos 
are cell-type-specific and regulated by some proteins and enzymatic activities. For example, 
up-regulation of heparanase influences exosomes secretion and their protein content [175].  
Taking together, this study suggests that exosomes actively participate in cell-to-cell 
communication. Since the exosomes also enter the pleural cavity, it is possible that their 
regulatory role involves pleural tissue at distance. Further dissemination with even more 
distant cells is then also possible when the effusion is drained through the stomata directly 
into lymphatic vesicles. The better understanding of the exosome function in malignant 








A theory that explains everything, explains nothing. 
                                                                                                   Karl Popper  
In this thesis work, we investigate the role of SDC-1 overexpression in angiogenesis and 
epithelial to mesenchymal transition. Further, we studied the potential value of ten 
angiogenesis-related factors, including SDC-1, as diagnostic and prognostic biomarkers for 
MPM. Lastly, we characterized pleural effusion derived EVs for a better understanding of 
MM tumor progression and metastasis. The major conclusions of this thesis work are: 
➢ SDC-1 over-expression effects growth factors secretion of mesothelioma cells. 
➢ SDC-1 overexpression inhibits endothelial cells proliferation, migration, and tube 
formation. 
➢ Loss of nuclear SDC-1 induce epithelial-mesenchymal transition in A549 lung 
adenocarcinoma cells. 
➢ Loss of nuclear SDC-1 increase B6FS fibrosarcoma cells invasion. 
➢ Galectin-1, mesothelin, osteopontin, shed SDC-1, VEGF, MMP-7, HGF, TIMP-1, 
and NRG1-β1 can be diagnostic biomarkers for distinguishing malignant pleural 
mesothelioma and metastatic adenocarcinoma from benign condition. 
➢ Galectin-1, mesothelin, MMP-7, and shed SDC-1 can be diagnostic biomarkers for 
distinguishing malignant pleural mesothelioma from metastatic lung adenocarcinoma 
patients. 
➢ VEGF and shed SDC-1 are prognostic biomarkers for malignant pleural 
mesothelioma. 
➢ Pleural effusion derived exosomes have higher level of osteopontin, galectin, 
mesothelin, and VEGF in malignant pleural mesothelioma patients compared with 
adenocarcinoma and benign conditions. 
➢ SDC-1 and HGF are present at higher level in exosomes isolated from pleural 





 FUTURE PERSPECTIVE 
The future is always beginning now. 
                                                          Mark Strand  
The aim of this thesis was to investigate the role of SDC-1 in angiogenesis of mesenchymal 
cells and its impact on epithelial to mesenchymal transition along with evaluation of the 
efficiency of SDC-1 in combination with other stablished biomarkers. Although we covered 
the aims of this thesis, there are more findings which merit further investigation.  
Our results showed that SDC-1 overexpression inhibits endothelial cell migration, 
proliferation, and tube formation. Additionally, we showed that nuclear SDC-1 reduces EMT 
in cancer cells. It will be interesting to study the mechanisms and pathways which are 
involved in these processes.  
Our results showed the presence of biological active proteins in exosomes. Further analysis to 
study the effect of tumor cell-derived exosomes on the neighbor cells by transferring their 







It is beautiful to be alone, it is also beautiful to be in love, to be with people. And they are 
complementary, not contradictory. 
                                                                                                                                   Osho  
The best part of my PhD is without question the people I had the honor of working with. At 
the end of this thesis, I would like to take some time to publicly acknowledge the people 
without whom this project would never have been possible. It has been a true privilege 
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